Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/ HER2– advanced or metastatic breast cancer in Spain
- Galve-Calvo, E.
- González-Haba, E.
- Gostkorzewicz, J.
- Martínez, I.
- Pérez-Mitru, A.
Revue:
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
Année de publication: 2018
Volumen: 10
Pages: 773-790
Type: Article
